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Background: The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive
care units (ICUs) in Europe.
Methods: A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries,
representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU).
Results: During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of
7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually
exclusive cumulative incidences of candidemia and IAC were 5.52 and 1.84 episodes per 1000 ICU admissions,
respectively. Crude 30-day mortality was 42%. Age (odds ratio [OR] 1.04 per year, 95% CI 1.02–1.06, p < 0.001),
severe hepatic failure (OR 3.25, 95% 1.31–8.08, p 0.011), SOFA score at the onset of IC (OR 1.11 per point, 95% CI
1.04–1.17, p 0.001), and septic shock (OR 2.12, 95% CI 1.24–3.63, p 0.006) were associated with increased 30-day
mortality in a secondary, exploratory analysis.
Conclusions: The cumulative incidence of IC in 23 European ICUs was 7.07 episodes per 1000 ICU admissions.
Future in-depth analyses will allow explaining part of the observed between-center variability, with the ultimate
aim of helping to improve local infection control and antifungal stewardship projects and interventions.
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Invasive candidiasis (IC) can develop in adult patients ad-
mitted in intensive care units (ICUs), with a significant
impact on morbidity, mortality, and healthcare costs [1–
4]. The most frequent clinical forms of IC in critically ill
patients are candidemia and intra-abdominal candidiasis
(IAC), which affect up to 5% of all ICU admissions [2, 5].
In the last 10 years, other series addressed specifically
the cumulative incidence of IC in the ICU setting [6–10].
The majority of those studies was limited to candidemia,
some were limited to one or a few countries, and some oc-
casionally included cases not representing true infections
but colonization [6–10].
The aim of the present multinational study was to ex-
pand our knowledge of the cumulative incidence of
ICU-acquired IC in Europe.
Material and methods
The present multicenter, retrospective study was con-
ducted from January 2015 to December 2016 in 23 ICUs
in 22 large tertiary care European hospitals (9 in Italy, 4
in France, 2 in Greece, 1 in Belgium, 1 in Czech Repub-
lic, 1 in Germany, 1 in Ireland, 1 in Portugal, 1 in Spain,
1 in The Netherlands, and 1 in the UK). All patients
who developed an episode of candidemia or a microbio-
logically documented IAC [11] during their stay in theTable 1 Multivariable analysis of center-level factors potentially asso
candidiasis in European ICUs
Center-level variables* Number of IC
episodes
Number of IC
admissions
Year of study
2015 271 40,642
2016 299 40,003
Type of ICU
Medical (n = 5) 149 7828
Surgical (n = 3) 51 29,087
Mixed (medical plus surgical, n = 15) 370 43,730
The sample size was of 46 observations (2 for each of the 23 participating ICUs, one
center as random effect. The model also included an interaction term (year of study
(including both candidemia and IAC) were confirmed in a subgroup analysis includ
observed increased cumulative incidence of IC in medical ICU vs. surgical ICU was m
1.55, p 0.619), type of ward (p 0.005, with CIR 0.03 for surgical vs. medical, 95% CI 0
type of ward (p for interaction 0.782), center as random intercept (standard deviatio
analysis of patients with IAC (n = 148) were as follows: year of study (CIR 1.77, 95%
medical, 95% CI 0.07–12.51, and CIR 0.82 for mixed vs. medical, 95% CI 0.12–5.37), y
intercept (standard deviation of the random effect = 1.565; model β0 = − 6.285). Stra
follows: Italy (2 medical and 7 mixed ICUs), 89.62 episodes per 1000 ICU admissions
episodes per 1000 ICU admissions (range 0.62–27.63); Greece (1 medical and 1 mix
ICU), 9.28 episodes per 1000 ICU admissions; Czech Republic (1 surgical ICU), 0.90 p
hospital admissions; Ireland (1 mixed ICU), 5.63 episodes per 1000 ICU admissions;
ICU), 10.46 episodes per 1000 ICU admissions; The Netherlands (1 mixed ICU), 2.29
ICU admissions
CI confidence intervals, CIR cumulative incidence ratio, IC invasive candidiasis, ICU in
*The model also includes center as a random intercept (standard deviation of the r
§p = 0.022 for the subgroup comparison surgical vs. medicalICU (at least 48 h after admission) were included in the
study.
The primary objective of the study was to assess the cu-
mulative incidence of ICU-acquired IC in European ICUs.
Secondary objectives were (i) to assess the independent im-
pact of center-level factors on the cumulative incidence of
ICU-acquired IC and (ii) to assess factors associated with
crude 30-day mortality in patients with ICU-acquired IC.
The entire EUCANDICU project consists of two
phases: (i) a first study describing the cumulative inci-
dence of ICU-acquired IC in Europe, reported in the
present paper; (ii) a second, case-control study to assess
patient-level predictors of ICU-acquired IC, which will
be conducted and published subsequently.
Definitions
ICU-acquired IC was defined as candidemia or IAC with
signs and symptoms of infection developing at least 48 h
after ICU admission. Candidemia and IAC were defined
according to previously published definitions [6, 11].
More in detail, candidemia was defined as the presence
of at least one positive blood culture for Candida spp. in
patients with signs and symptoms of infection. IAC was
defined as the presence of at least one of the following:
(i) Candida detection by direct microscopy or growth in
culture from necrotic or purulent intra-abdominalciated with changes in the cumulative incidence of invasive
U Cumulative incidence
(IC episodes/1000 ICU admissions)
CIR (95% CI) p
0.313
6.67 Ref
7.47 1.18 (0.85–1.63)
0.073
19.03 Ref
1.75 0.10 (0.01–0.76)§
8.46 0.40 (0.10–1.63)
in 2015 and one in 2016). Non-independence was accounted by adding
× type of ICU), with p for interaction 0.761. Results of the main model
ing only patients with candidemia and not IAC (n = 422), suggesting that the
ainly due to candidemia and not IAC: year of study (CIR 1.09, 95% CI 0.77–
.00–0.31, and CIR 0.34 for mixed vs. medical, 95% CI 0.07–1.55), year of study ×
n of the random effect = 1.410; model β0 = − 3.937). Results of the subgroup
CI 0.79–4.21, p 0.177), type of ward (p 0.798, with CIR 0.94 for surgical vs.
ear of study × type of ward (p for interaction 0.290), center as random
tified cumulative incidences for countries in the entire study period was as
(range 1.20–114.21); France (2 surgical, 1 medical, and 1 mixed ICUs), 11.85
ed ICUs), 30.79 per 1000 ICU admissions (range 7.50–45.73); Belgium (1 medical
er 1000 ICU admissions; Germany (1 mixed ICU), 42.43 episodes per 1000
Portugal (1 mixed ICU), 9.33 episodes per 1000 ICU admissions; Spain (1 mixed
episodes per 1000 ICU admissions; UK (1 mixed ICU), 41.67 episodes per 1000
tensive care unit, IQR interquartile range
andom effect = 1.293; model β0 = − 3.763)
Fig. 1 Cumulative incidence of ICU-acquired invasive candidiasis.
IAC, intra-abdominal candidiasis; IC, invasive candidiasis; ICU, intensive
care unit
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ing surgery; (ii) growth of Candida from the bile or
intra-biliary duct devices, plus biopsy of intra-abdominal
organs; (iii) growth of Candida from blood cultures in
the presence of secondary or tertiary peritonitis in the
presence of no other pathogens; (iv) growth of Candida
from drainage tubes inserted less than 24 h before cul-
ture sampling [11]. In case of multiple episodes of IC in
the same patient, a subsequent event was considered as
independent if developing at least 30 days after the last
positive culture related to the previous episode. Crude
30-day mortality was defined as death within 30 days
from the onset of signs and symptoms of ICU-acquired
IC. All patients suitable for inclusion were identified
starting from the laboratory databases of the participat-
ing hospitals, and subsequent review of clinical records.
Statistical analysis
The cumulative incidence of ICU-acquired IC was mea-
sured as the number of episodes per 1000 ICU admis-
sions. The impact of center-level factors on the
cumulative incidence of ICU-acquired IC was assessed
by means of a multivariable generalized Poisson mixed
model with center as a random intercept, after having
verified the absence of overdispersion in count data.
Subgroup analyses were also conducted according to the
type of ICU-acquired IC (candidemia and IAC).
Demographic and clinical characteristics of patients
are presented with number and percentage for categor-
ical variables and median and interquartile range (IQR)
for continuous variables. Their possible association with
crude 30-day mortality was firstly tested through uni-
variable logistic regression. Then, factors potentially as-
sociated with the outcome in univariable comparisons
(p < 0.10) were included in an initial multivariable re-
gression model and further selected for the final multi-
variable model (model A) by means of a stepwise
backward procedure based on the Akaike information
criterion. Only the first IC episode per patient was con-
sidered for this analysis. Variables included in model A
were also included in an additional multivariable mixed
logistic regression model (model B), with center as a
random intercept.
All the analyses were conducted using R Statistical
Software 3.5.2 (R Foundation for Statistical Computing,
Vienna, Austria). Mixed models were built using the
glmer function in the lme4 package.
Results
Primary analysis—cumulative incidence
During the study period, the 23 ICUs (median number of
beds 18, interquartile range 14–43) had 80,645 admissions
and 570 episodes of ICU-acquired IC, corresponding to
an incidence of 7.07 episodes per 1000 ICU admissions(6.67 and 7.47 in 2015 and 2016, respectively). Separated,
non-mutually exclusive incidences of candidemia and IAC
were 5.52 and 1.84 episodes per 1000 ICU admissions, re-
spectively. As shown in Table 1, in subgroup comparisons,
admission to a surgical ICU was associated with lower in-
cidence when compared with a medical ICU (cumulative
incidence ratio 0.10, 95% CI 0.01–0.76 for surgical vs.
medical, p 0.022). The observed random effects variance
testified to the presence of between-center variability in
the cumulative incidence of IC that was unexplained by
the explored, fixed center-level predictors (Table 1 legend)
. A graphic representation of the cumulative incidence of
IC is also available in Fig. 1.
Secondary analysis—predictors of mortality
An additional, secondary analysis of predictors of mortality
was conducted in the subgroup of patients for whom patient-
level clinical data was registered (mostly cases of IC meeting
the following inclusion criterion for the future case-control
Table 2 Univariable and multivariable analyses of factors associated with crude 30-day mortality in patients with ICU-acquired IC
Variable Total of
patients (%)
n = 330 (100)
Non-survivors
(%)
n = 137 (42)
Survivors (%)
N = 193 (58)
Univariable analysis Multivariable analysis*
OR (95% CI) p OR (95% CI) p
Demographics
Age in years, median (IQR) 66 (55–75) 68 (59–77) 64 (51–73) 1.03 (1.01–1.05) 0.001 1.04 (1.02–1.06) < 0.001
Male gender 198 (60) 84 (61) 114 (59) 1.10 (0.70–1.72) 0.681
Medical history
Diabetes mellitus 73 (22) 34 (25) 39 (20) 1.30 (0.77–2.20) 0.321
COPD 44 (13) 22 (16) 22 (11) 1.49 (0.79–2.81) 0.222
End-stage chronic renal disease 59 (18) 35 (26) 24 (12) 2.42 (1.36–4.29) 0.003 1.82 (0.96–3.45) 0.068
Severe hepatic failurea 29 (9) 18 (13) 11 (6) 2.50 (1.14–5.49) 0.022 3.25 (1.31–8.08) 0.011
Solid tumor 94 (28) 40 (29) 54 (28) 1.06 (0.65–1.72) 0.809
Hematological malignancy 16 (5) 5 (4) 11 (6) 0.63 (0.21–1.85) 0.397
Solid organ transplant 18 (5) 5 (4) 13 (7) 0.52 (0.18–1.51) 0.231
Steroid treatment 43 (13) 20 (15) 23 (12) 1.26 (0.66–2.41) 0.477
Immunosuppressants other than steroids 30 (9) 13 (9) 17 (9) 1.09 (0.51–2.32) 0.832
Age-adjusted Charlson score 6 (3–7) 6 (5–8) 5 (3–7) 1.16 (1.07–1.25) < 0.001
Recent exposures (within 30 days)
Previous abdominal surgery 174 (53) 65 (47) 109 (56) 0.70 (0.45–1.08) 0.106
Previous antibacterial therapy 226 (68) 102 (74) 124 (64) 1.62 (1.00–2.63) 0.050 1.53 (0.89–2.64) 0.124
Previous echinocandins 35 (11) 12 (9) 23 (12) 0.71 (0.34–1.48) 0.360
Previous azoles 53 (16) 22 (16) 31 (16) 1.00 (0.55–1.82) 0.999
Previous amphotericin B 5 (2) 4 (3) 1 (1) 5.77 (0.64–52.24) 0.119
Baseline variables**
SOFA score, median (IQR) 9 (5–12) 10 (7–13) 7 (4–10) 1.16 (1.10–1.22) < 0.001 1.11 (1.04–1.17) 0.001
SAPS II score, median (IQR) 48 (35–64) 55 (40–72) 43 (31–56) 1.03 (1.02–1.04) < 0.001
Length of ICU stay in days (IQR) 8 (3–19) 9 (3–20) 8 (3–18) 1.00 (0.99–1.01) 0.469
WBC (cells × 109/L), median (IQR) 13.6 (8.2–20.2) 13.2 (7.5–20.0) 13.9 (8.8–20.7) 0.99 (0.98–1.01) 0.497
AKI§ 157 (48) 81 (59) 76 (39) 2.23 (1.43–3.48) < 0.001
Infection variables
Type of IC 0.193
IAC 97 (29) 34 (25) 63 (33) (ref)
Candidemia 215 (65) 97 (71) 118 (61) 1.52 (0.93–2.50)
IAC plus candidemia 18 (5) 6 (4) 12 (6) 0.93 (0.32–2.69)
Candida species 0.866
Candida albicans 162 (49) 65 (47) 97 (50) (ref)
Non-Candida albicans§§ 141 (43) 60 (40) 81 (42) 1.11 (0.70–1.75)
Candida albicans plus non-Candida albicans§§§ 27 (8) 12 (9) 15 (8) 1.19 (0.53–2.72)
Presence of septic shockb 165 (50) 91 (66) 74 (38) 3.18 (2.01–5.03) < 0.001 2.12 (1.24–3.63) 0.006
Presence of endocarditis 8 (2) 3 (2) 5 (3) 0.84 (0.20–3.58) 0.816
Fluconazole resistancec 66 (24) 28 (25) 38 (23) 1.01 (0.65–1.99) 0.665
Early treatment variables***
Adequate source control within 24 hd 205 (62) 73 (53) 132 (68) 0.53 (0.34–0.83) 0.006 0.65 (0.39–1.07) 0.093
Adequate empiric antifungals within 24 he 93 (36) 35 (36) 58 (36) 0.97 (0.57–1.63) 0.902
Results are presented as n (%) unless otherwise indicated. AKI acute kidney injury, COPD chronic obstructive pulmonary disease, CVC central venous catheter, IC
invasive candidiasis, IAC intra-abdominal candidiasis, ICU intensive care unit, IQR interquartile range, SAPS simplified acute physiology score, SOFA sequential organ
failure assessment, WBC white blood cells
*Only results for variables retained in the final multivariable model (model A) are presented. Variables included in model A were also included in an additional generalized linear
multivariable mixed logistic regression model with center as a random intercept (model B; standard deviation of the random effect=0.311; model β0=−4.329), the results of which were in
line with those of model A: age (OR 1.04, 95% CI 1.02–1.06, p <0.001); end-stage chronic renal disease (OR 1.83, 95% IC 0.95–3.52, p 0.070), severe liver failure (OR 3.41, 95% CI 1.33–8.73, p
0.010); previous antibacterial therapy (OR 1.51, 95% CI 0.86–2.63, p 0.148); SOFA score (OR 1.11, 95% CI 1.04–1.18, p 0.001); septic shock (OR 2.09, 95% CI 1.21–3.62, p 0.008), adequate
source control within 24h (OR 0.64, 95% CI 0.38–1.08, p 0.095). The Akaike information criterion (AIC) values for model A and model B were 391.1 and 392.5, respectively
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**At the onset of signs and symptoms of IC
***The present exploratory model was not developed to comprehensively assess the overall impact of antifungal therapy and/or adequate source control
(including those performed beyond 24 h after the onset of symptoms), which needs further dedicated investigation to be reliably evaluated
§ClCr < 60 mL/min
§§C. glabrata (n = 52), C. parapsilosis (n = 38), C. tropicalis (n = 18), C. krusei (n = 14), C. dubliniensis (n = 4), other species with lower frequency (n = 5), more than one
non-Candida albicans spp. concomitantly (n = 10)
§§§C. albicans plus C. glabrata (n = 16), C. albicans plus C. parapsilosis (n = 4), other combinations with lower frequency (n = 7)
aSevere hepatic failure was defined as liver cirrhosis according to histology or in the presence of a clinical diagnosis supported by laboratory, endoscopy, and
radiologic findings
bSeptic shock was defined as hypotension not responding to fluid therapy and requiring vasoactive agents
cInformation available (i.e., fluconazole tested) for 274/330 patients (83%)
dSource control was considered adequate in the following cases: (i) not necessary, (ii) devices or foreign body removal, (iii) drainage of infected fluid collections,
(iv) debridement of infected solid tissue, and (v) definitive measures to correct anatomic derangements resulting in ongoing microbial contamination
eFrom the onset of signs and symptoms of IC. Empiric treatment was considered adequate when the infecting organism was ultimately shown to be susceptible
to the empirically administered antifungal. This analysis was conducted in the subgroup of patients not receiving empirical antifungal or receiving empirical
antifungals for treating Candida spp. for which susceptibility test results were subsequently available (257/330, 78%)
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without IC). In this regard, clinical data were available for
330/570 cases of IC (58%). The median age of patients was
66 (IQR 55–75), and 60% were males (198/330). Candidemia,
IAC, and IAC plus candidemia accounted for 65% (215/330),
29% (97/330), and 5% (18/330) of episodes, respectively. C.
albicans was the most frequently isolated species (189/330,
57%), followed by C. glabrata (68/330, 21%) and C. parapsilo-
sis (42/330, 13%). Crude 30-day mortality was 42% (137/330).
Table 2 shows univariable and multivariable analyses of pre-
dictors of crude 30-day mortality. In the final multivariable
model (model A), age (odds ratio [OR] 1.04 per year, 95% CI
1.02–1.06, p < 0.001), severe hepatic failure (OR 3.25, 95%
1.31–8.08, p 0.011), SOFA score at the onset of IC (OR 1.11
per point, 95% CI 1.04–1.17, p 0.001), and septic
shock (OR 2.12, 95% CI 1.24–3.36, p 0.006) were as-
sociated with increased 30-day mortality. As reported
in the legend of Table 2, the additional multivariable
model with center as random intercept (model B)
confirmed the results obtained in model A.
Discussion
This is the largest multinational study assessing the
cumulative incidence of ICU-acquired IC in Europe to date.
Based on our report, the incidence of IC in European ICUs
was 7.07 episodes per 1000 ICU admissions, with crude 30-
day mortality of 42%.
Our results are similar to those of the large point-
prevalence EPIC II study, which previously reported a
prevalence of 6.87 episodes of candidemia per 1000 ICU
patients, although we recorded a slightly lower cumula-
tive incidence of candidemia (5.52 episodes per 1000
ICU admissions) [6]. In addition, our analysis indicated
two center-level factors that may influence local inci-
dences: (i) the type of ICU, with medical ICUs being as-
sociated with increased incidence vs. surgical ICUs in
subgroup comparisons, and (ii) the presence of random
between-center variability, although likely relying in part
on unexplored but exhaustive center-level factors. It is
also worth noting that some unexplored center-level fac-
tors (e.g., cumulative days at risk, antifungal prophylaxis
policies), together with the low number (and thus lowgeneralizability) of ICU wards included in the subgroup
comparison surgical vs. medical (3 vs. 5, respectively),
might have influenced the unexpected but significant
observation of a lower cumulative incidence of IC in sur-
gical ICUs, which calls for future confirmatory studies
specifically addressing this aspect.
In a secondary analysis, we confirmed the importance of
baseline factors (age, severe hepatic failure) and severity of
disease/clinical presentation (SOFA score, septic shock) in un-
favorably influencing the prognosis of ICU-acquired IC [2,
12]. However, we could not explore the impact on mortality
of both source control and antifungal therapy performed/ad-
ministered beyond 24 h after the onset of IC. Dedicated stud-
ies and models aimed at primarily evaluating these variables
are necessary to comprehensively assess their effect.
An important limitation of our study is the limited number
of assessed, potential center-level predictors of cumulative in-
cidence. Further studies with a higher number of participating
ICUs are necessary for allowing inclusion of more variables in
the model. Other main limitations of our study are the lack
of a control group (patients without IC) for assessing patient-
level predictors of IC and the inherent possibility of having
considered some contamination as IAC. As regards the
former, it should be noted that the main goal in which we
were interested in this first phase was to provide a center-
level perspective on the cumulative incidence of ICU-
acquired IC, by describing its burden and assessing the pos-
sible effect of fixed and random center-level predictors. Al-
though it will ultimately add to the discussion, the assessment
of patient-level predictors is an independent and different
analysis, which will be the core of the future case-control
study. As regards the possibility of including contaminations,
it is worth noting that we used a consensus definition for
minimizing the number of contaminations misidentified as
IAC [11]. Another limitation is that most data came from a
few countries (e.g., 9/23 participating ICUs are in Italy), thus
preventing us from reliably assessing the existence of any pos-
sible between-country variability impacting on the cumulative
incidence of ICU-acquired IC. Finally, it should be acknowl-
edged that the impact on mortality of some covariates (e.g.,
COPD) may depend on their degree of severity, which was
not registered.
Bassetti et al. Critical Care          (2019) 23:219 Page 6 of 7Conclusions
Global incidence of IC in 23 European ICUs was 7.07 epi-
sodes per 1000 ICU admissions. Future in-depth analyses
will allow explaining part of the observed between-center
variability, with the ultimate aim of helping to improve local
infection control and antifungal stewardship interventions.
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